Modern Medicine Feature Articles

Do you prescribe MET for stone patients?Urology Times reached out to three urologists (selected randomly) and asked them each the following question: Do you prescribe MET for stone patients?
Building a patient education programPatient education can be a powerful tool that complements your expertise and boosts patient engagement.
The big squeezeLimited provider networks are cutting more than costs; these narrow networks are cutting dermatologists. One expert shares insight on what derms need to know.
Consolidation: What it looks like in dermatologyConsolidation is occurring throughout healthcare. An expert talks about what it means to practicing dermatologists.
Black female physicians face challenges just doing their jobs
Black female physicians face challenges just doing their jobsWhen Melanie Gordon, MD, FACP, walks into a patient’s room at the John H. Stroger Hospital of Cook County in Chicago, she’s frequently misidentified as a nurse, a dietician or someone else.
12-month results with small-aperture IOL providing patients with an extended range of vision
Confocal scanner gives ophthalmologists valuable new tool
Who is being tested for BRCA?A study looks at who is being tested for BRCA mutations as testing becomes more common. Also, a look at the impact of Zika virus on birth defects using benchmark data. Plus: How is the United States doing with infant mortality?
Year-2 Protocol T data paints different scenario from year-1The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol T—the first head-to-head-to-head comparison among aflibercept (Eylea, Renegeron Pharmaceuticals), ranibizumab (Lucentis, Genentech), and bevacizumab (Avastin, Genentech)—found in its first-year results that all three agents improved vision and reduced edema effectively.
DAVE study found little benefit of anti-VEGF/PRP for DMEThe scientific community knows that vascular endothelial growth factor (VEGF) causes increased, vascular permeability, resulting in diabetic macular edema (DME) in the ischemic retina, but how to stop the VEGF drive remains the challenge.